MINNEAPOLIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the fourth quarter and full year 2025 after the close of trading on Wednesday, February 11. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this li ...

MINNEAPOLIS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Inspire is scheduled to present at 12:45 p.m. Eastern Time. The presentation will be accessible via a live web ...

Core Insights - Inspire Medical Systems, Inc. specializes in innovative medical solutions for sleep apnea treatments, particularly through its Inspire therapy device, which serves as an alternative to CPAP machines [1] - Piper Sandler has set a price target of $165 for INSP, indicating a potential upside of 20.61% from the current trading price of $136.81 [1][6] Legal Issues - Inspire Medical is currently facing a class action lawsuit led by the Schall Law Firm, alleging violations of the Securities Exchange Act of 1934 related to securities fraud [2][5] - The lawsuit targets investors who purchased INSP securities between August 6, 2024, and August 4, 2025, with affected shareholders encouraged to contact the law firm by January 5, 2026 [3] Stock Performance - As of the latest update, INSP's stock price is $136.81, reflecting a decrease of 2.30% or $3.22, with trading fluctuations between $136.61 and $142.26 [4] - Over the past year, INSP has experienced significant volatility, with a high of $216.01 and a low of $70.77, and currently holds a market capitalization of approximately $4.05 billion [4][6]

Core Viewpoint - Inspire Medical Systems, Inc. is recognized for its innovative sleep apnea treatment solutions, particularly the Inspire therapy device, while facing a class action lawsuit that may impact investor sentiment [1][2][5] Company Overview - Inspire Medical Systems specializes in medical solutions for sleep apnea, particularly through its implantable Inspire therapy device [1] - The company's current stock price is $89.87, reflecting a recent increase of 7.92% or $6.60 [3][5] - The market capitalization of Inspire Medical Systems is approximately $2.66 billion, indicating its significant presence in the market [3] Analyst Ratings - Stifel Nicolaus has upgraded Inspire Medical Systems to a "Buy" rating with a price target of $110, suggesting a potential increase of 22.4% from the current stock price [1][5] Legal Challenges - The company is currently involved in a class action lawsuit led by the Schall Law Firm, alleging violations of the Securities Exchange Act of 1934, affecting investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2][5] - Shareholders who have experienced losses are encouraged to contact the law firm before January 5, 2026 [2] Trading Activity - The trading volume for INSP on the NYSE is 1,073,158 shares, indicating active investor interest despite ongoing legal challenges [4][5] - The stock has fluctuated between $83.37 and $90.55 today, with a yearly high of $216.01 and a low of $70.77 [3]

Group 1 - Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [3] - The company will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 11:30 a.m. Eastern Time [1][2] - Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $224.5 million, a 10% increase from $203.2 million in Q3 2024 [15] - U.S. revenue was $214.4 million, up 9% from $195.8 million in the prior year [15] - Gross margin improved to 85.8% from 84.1% year-over-year, driven by increased sales volume and a favorable sales mix of Inspire 5 [15] - Operating income decreased to $9.6 million from $14.3 million in the prior year [16] - Net income for the quarter was $9.9 million, down from $18.5 million year-over-year [16] - Adjusted EBITDA was $44 million, slightly down from $44.5 million in the prior year [17] - The company increased its earnings per share guidance to $0.90-$1, up from $0.40-$0.50 previously [9] Business Line Data and Key Metrics Changes - Inspire 5's U.S. launch showed significant progress, with physician training over 98% complete and contracting over 90% complete for centers [8] - The Inspire 5 system demonstrated an 87% inspiratory overlap with patients' breathing, indicating strong clinical performance [5] - The company reported a 20% reduction in surgical times based on clinical studies [4] Market Data and Key Metrics Changes - Revenue outside the U.S. was $10.1 million, a 37% increase year-over-year [15] - The Centers for Medicare & Medicaid Services (CMS) finalized an 11% increase in the physician fee schedule for CPT code 64568, effective January 1, 2026 [10] Company Strategy and Development Direction - The company remains focused on patient outcomes and innovation, investing in clinical evidence and medical education [4] - Strategies include training advanced practice providers and increasing the capacity of provider partners to treat more patients [13] - The company is optimistic about the future, with plans to drive long-term stakeholder value [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of growth heading into 2026, with an early indication of 10%-11% growth for next year [22] - The company is mindful of near-term factors such as inventory transitions and competitive activity but remains focused on executing its growth strategy [23] - Management highlighted the positive impact of GLP-1s on patient flow into clinics, which could benefit Inspire therapy [12] Other Important Information - The company completed $50 million in share repurchases during the quarter, totaling $125 million year-to-date [17] - The company ended the quarter with $411 million in cash and investments, allowing for continued investment in growth strategies [17] Q&A Session Summary Question: Thoughts on 2026 planning and cadence - Management is focused on finishing Q4 strong and is still early in the 2026 planning process, indicating potential accelerated growth from Q3 [22] Question: Trends in business for October and Q4 guidance - Management noted strong trends with Inspire 5 and expects to see consistent execution and operational benefits from tighter integration across departments [28] Question: Transitioning centers to Inspire 5 - Management confirmed that while many centers are transitioning to Inspire 5, some will continue to use Inspire 4 for economic reasons [32] Question: Operating expenses and sustainability - Management indicated that while there is a focus on expense control, investments in R&D and marketing will continue, with a disciplined approach to spending [36] Question: Impact of new competitors on market growth - Management stated that it is early days for new competitors and they will continue to monitor the situation closely [64] Question: Economic considerations for centers using Inspire 4 - Management clarified that economic factors are more related to site of service reimbursement rather than physician reimbursement rates [82] Question: Operating expenses trend for 2026 - Management expects a slight increase in DTC spending but does not anticipate it to grow at the same rate as revenue [83]

Core Insights - Inspire Medical Systems reported strong financial results for Q3 2025, with a focus on the transition to the Inspire V system and positive global performance [3][4]. Recent Business Highlights - The company presented clinical evidence at industry meetings showing that the Inspire V system has enhanced performance compared to legacy systems [3]. - A successful device implant rate of 100% was reported in studies conducted in Singapore and the U.S. [3]. - The Inspire V system demonstrated a 20% reduction in surgical procedure time and significant reductions in disease severity [3]. - Over 75% of centers are ready to transition to the Inspire V system, indicating strong progress in the U.S. launch [3]. Third Quarter 2025 Financial Results - Revenue for Q3 2025 was $224.5 million, a 10% increase from $203.2 million in Q3 2024 [4]. - U.S. revenue was $214.4 million, up 9% year-over-year, while international revenue reached $10.1 million, a 37% increase [4]. - Gross margin improved to 85.8% from 84.1% in the prior year, attributed to higher sales volume and a favorable sales mix [5]. Operating Expenses and Income - Operating expenses rose to $183.1 million, a 17% increase from $156.5 million in Q3 2024, mainly due to marketing and corporate costs [6]. - Operating income decreased to $9.6 million from $14.3 million in the prior year [7]. Net Income and Earnings Per Share - Net income for Q3 2025 was $9.9 million, down from $18.5 million in Q3 2024 [8]. - Diluted net income per share was $0.34, compared to $0.60 in the prior year [8]. Full Year 2025 Guidance - The company maintains its revenue guidance for 2025 at $900 million to $910 million, reflecting a growth of 12% to 13% over 2024 [11]. - Gross margin guidance remains at 84% to 86%, with an increased diluted net income per share guidance of $0.90 to $1.00 [11]. Cash Position - As of September 30, 2025, cash, cash equivalents, and investments totaled $410.9 million, down from $516.5 million at the end of 2024 [10]. Share Repurchase - The company completed a $50 million share repurchase, indicating confidence in its financial position [9].

Core Insights - Inspire Medical Systems, Inc. is set to present at the 2025 UBS Global Healthcare Conference on November 10, 2025, at 11:45 a.m. Eastern Time [1][2] - The company specializes in innovative, minimally invasive solutions for patients suffering from obstructive sleep apnea [3] Company Overview - Inspire Medical Systems focuses on the development and commercialization of proprietary Inspire therapy, which is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [3] - The company aims to provide safe and effective treatment options for patients with this condition [3] Presentation Details - The presentation will be available via a live webcast, with a replay accessible for two weeks afterward in the Event Archive section of Inspire's Investor website [2]

Core Viewpoint - Inspire Medical Systems, Inc. is set to release its financial results for Q3 2025 on November 3, 2025, followed by a conference call to discuss these results and recent business developments [1]. Financial Results Announcement - The financial results for the third quarter of 2025 will be released after the close of trading on November 3 [1]. - A conference call will be hosted by Inspire's management team at 5:00 p.m. Eastern Time on the same day to discuss the results [1]. Webcast and Participation - A webcast of the conference call will be available on the Investor Relations page of Inspire's website [2]. - For those wishing to ask questions, registration is required, and an email will be sent with dial-in details and a unique access code [3]. - The company recommends registering at least 10 minutes before the call to ensure connection [3]. Replay Availability - A replay of the conference call will be accessible on the Investor Relations website approximately two hours after the event and will be archived for two weeks [4]. Company Overview - Inspire Medical Systems focuses on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [5]. - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [5].

Company Overview - Inspire Medical Systems, Inc. is a medical technology company focused on developing and commercializing innovative, minimally invasive solutions for patients with obstructive sleep apnea [4] - The company's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea [4] Leadership Change - Chief Financial Officer Rick Buchholz will step down effective December 31, 2025, to pursue other professional opportunities, but will remain in a financial advisory role until February 28, 2026, to ensure a smooth transition [1][2] - Buchholz has been with the company since 2014 and has played a significant role in its growth, including increasing revenue from $4 million to over $800 million in 2024 [2] Financial Guidance - The company reaffirms its full-year 2025 revenue guidance of $900 to $910 million, with a gross margin guidance of 84% to 86% and diluted net income per share guidance of $0.40 to $0.50 [3]